The role of estrogens is now increasingly well established, and considerable advances in the understanding of their molecular mechanism of action have been achieved with recombinant human estrogen receptors a (hERa) and b (hERb). [11] [12] [13] Hormone-bound receptors form an active dimer that mediates biological response in the nucleus by interacting with specific short nucleotide sequences of DNA called estrogen response elements (EREs) located in the promoter region of target genes. Numerous co-activators or corepressors are involved in the associated activation processes of the transcriptional machinery, leading to the biological cellular response (Fig. 1 ). [14] [15] [16] [17] Xenoestrogens are synthetic compounds that encompass the simple phenolic structure of steroidal estrogens. Nonsteroidal estrogens are being increasingly developed and span a remarkable range of acyclic structures with a great variety of heterocycles. 18, 19) This is the case of many natural derivatives with a coumarinic, flavone, or flavene core structure. 20) Among these natural phytoestrogens, coumestanes with a coumarinic structure are mainly represented by one derivative, coumestrol. 21, 22) In our work to develop new active xenoestrogens, we have recently reported the 6,12-dihydro-3-methoxy-1-benzopyrano [3,4-b] [1, 4] benzothiazin-6-one (1) that appeared to compete with E2 for ER binding on MCF-7 breast cancer cells. 10) The present work further analyses the estrogenic activity of this compound on MVLN cells (ERE-regulated luciferase expression cells) in comparison with E2, coumestrol, and the pure antiestrogen RU 58668. 23 24, 25) and concerning the subcellular localization of the analogous compound 15 suggested an intranuclear localization. Such results confirm our preliminary results, 10) suggesting the involvment of ERs in the biological activity of 1. A binding mode for 1 within the human estrogen receptor aligand binding domain (hERa-LBD) is proposed.
MATERIALS AND METHODS

Compounds Utilized Estradiol and tritium-labeled estradiol [
3 H]-17b-E2 were purchased from Sigma (Bornem, Belgium) and Amersham Pharmacia (Roosendaal, the Nether--lands), respectively. Coumestrol was purchased from Fluka (Bornem, Belgium) and RU 58668 was obtained from Roussel Uclaf (Romainville, France). Starting materials for the synthesis of compounds 15 and 16 were purchased from Acros Organics (Noisy-le-Grand, France) for 4-hydroxy-7-methoxycoumarin (2) and from Aldrich Chemical Company (Sigma Aldrich, Saint-Quentin Fallavier, France) for 4-hydroxycoumarin (3), 4-fluoroaniline (4), 4-methoxyaniline (5), and ammonium thiocyanate (6) . Compound 1 was obtained according to the procedure described by Tabakovic et al. 26) Its spectral and physicochemical characteristics have been previously reported. 10) Melting points were determined on a Kofler Heizbank Reichert 18.43.21 and were uncorrected. IR spectra were recorded on a Shimadzu FTIR-8201PC spectrometer in potassium bromide pellets (n in cm
Ϫ1
). NMR spectra in DMSO-d 6 were recorded on a Bruker AC 300 spectrometer. Chemical shifts d are given in ppm and coupling constants J are expressed in Hz. The following abreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; and m, multiplet. MS spectra were recorded on a Nermag R10-10H apparatus by electron impact (EI).
4-Fluorophenylthiourea (9) and 4-Methoxyphenylthiourea (10) Compounds 9 and 10 were prepared following the synthetic route illustrated in Chart 2 27, 28) : 4-fluoroaniline hydrochloride (7) or 0.01 mol of 4-methoxyaniline hydrochloride (8) , respectively, were obtained by adding slowly concentrated hydrochloric acid on the appropriate aniline dissolved in CH 2 Cl 2 . To 0.01 mol of the substituted aniline hydrochlorides was added 0.01 mol of ammonium thiocyanate (6) in 100 ml of water. The mixture was refluxed for 4 h. On cooling at room temperature, the precipitate was filtered under vacuum, rinsed 4 times with cold water, and dried to give, respectively, 4-fluorophenylthiourea (9) or 4-methoxyphenylthiourea (10 2-Amino-6-fluorobenzothiazole (11) and 2-Amino-6-methoxybenzothiazole (12) 10 mmol of 9 or 10 were added to 50 ml of distilled chloroform at 5°C and 0.01 mol of bromine was added dropwise. The mixture was allowed to stand at room temperature for 1 h and was refluxed for 1 h. After cooling at room temperature, the mixture was treated with an aqueous solution of sulfurous acid and filtered. Concentrated ammonium hydroxyde was added to the filtrate, and the crude precipitate corresponding to 2-amino-6-fluorobenzothiazole (11) or 2-amino-6-methoxybenzothiazole (12), respectively, was filtered and dried under vacuum. 
2-Amino-5-fluorothiophenol (13) and 2-Amino-5-methoxythiophenol (14)
Compounds 11 or 12 were refluxed in a 12 N solution of acquous sodium hydroxyde for 48 h. After standing at room temperature, the mixture was filtered in glacial acetic acid and yellow crystals appeared, corresponding to the unstable 2-amino-5-methoxythiophenol (14) . [29] [30] [31] [32] Compound 13 was obtained as a yellow oil and used later without further purification.
14: Yellow needles, yield: 51%, C 7 H 9 NOS, mp 106°C. IR (KBr) cm 
. Receptor Binding Studies Highly purified recombinants hERa or b were purchassed from Calbiochem, EuroBiochem, Bruges, Belgium. These commercial preparations were diluted 300 times in a bovine serum albumin (BSA) solution (1 mg/ml) to be subsequently adsorbed onto hydroxyapatite (HAP) according to the procedure of Maaroufi and Leclercq (1994) . 33) After removal of unbound material by centrifugation, the HAP suspensions were incubated overnight at 0-4°C with [ 3 H]E2 in the presence or the absence of increasing amounts of E2 (control) or the investigated compound (from 10 nM to 1 mM). Suspensions were centrifuged and the corresponding pellets were washed. Radioactivity adsorbed onto the HAP pellets was extracted with ethanol and measured by liquid scintillation counting. 35) ) were cultured for 3 to 4 d in f35-mm Falcon dishes (plating density 80000 cells/dish) in fetal calf serum depleted of endogenous steroid by dextran-coated charcoal (DCC) treatment. Compounds 1, 15, 16, coumestrol (from 10 Ϫ6 M to 10 Ϫ10 M), E2 0.1 nM, and RU 58668 10 Ϫ7 M were added to the medium and cultured until firefly luciferase was detected (24 h). For that purpose, the medium was removed and the cells were washed twice with a phosphate-buffered saline (PBS) solution. A minimal volume (250 ml) of a 5-fold diluted lysis solution (E153A Promega, Leiden, the Netherlands) was then added to the dishes and the latter maintained under mild agitation for 20 min to extract luciferase. Lysed cells were subsequently detached with a scraper (Costar 3010) and centrifuged for 5 s at 12000ϫg to clarify their extracts. Twenty microliters of each extract were finally mixed at room temperature with 100 ml of a luciferase-reactant medium (Promega E151A/E152A), prepared according to the manufacturer's protocol. Induced light was then measured with a Berthold luminometer (Luma LB 9507) and induction of the ERE-dependent biological response was expressed in arbitrary units with regard to the light measured with a blank (relative light unit, RLU). To compare RLUs, the protein content of each extract was measured using the Coomassie method (PIERCE, Erembodegem, Belgium).
Influence of Compounds on ER Level
The statistical significance of differences among values was assessed by Student's t-test. Differences vs. control were considered significant at pϽ0.01. It should be noted that pϽ0.01 was reached for all the pharmacological data reported in this work.
Ion Microscopy The monolayer cell culture was washed in PBS 10 ml and cells were dissociated in 0.02% trypsin-EDTA medium. MCF-7 cells were cultured on thin ultrapure gold plates with a surface of 1 cm 2 and thickness of 0.05 cm (ENGELHARD-CLAL, Noisy-le-Sec, France). MCF-7 cells were purchased from the ATCC (American Type Culture Collection, ref. HTB22, Biovalley, Conches, France) and maintained in DMEM containing phenol red (Sigma) and supplemented with 15 nM N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES), 2 mM glutamine, and 1% of an antibiotic cocktail (streptomycin 10 mg/ml, penicillin 10000 U/ml, amphotericin B 25 mg/ml). Cell incubation (1.5 h) was carried out by adding a solution of compound 15 at 10 Ϫ6 M to the DMEM medium. Compound 15 was made soluble in DMSO and was diluted by a factor of 1000 in the DMEM culture medium. Unbound ligands were removed with 0.01 M cacodylate buffer (pH 7.4) and the thin gold plates were fixed with 1.2% glutaraldehyde for 30 min at 4°C. The plates were washed with 0.1 M cacodylate buffer and with deionized and distilled water to eliminate buffer salts. Residual water was then eliminated with filter paper. Plates were then stored at 37°C for 48 h to dry the preparation before analysis. Ion microscopy, based on selected ion monitoring mass spectrometry (SIM mode) allowed us to distinguish CN (Mϭ26) and F (Mϭ19), providing separate images reflecting the distribution of incorporated fluor. Analysis was carried out at high mass resolution (M/DM) close to 3000 to avoid interference by polyatomic ions. The histologic photographs were obtained with an exposure of 5 s for Mϭ26, which allowed detection of an ionic current of 8.1 · 10 Ϫ14 A. On the other hand, exposure of 4 min for Mϭ19 was necessary to detect an ionic current of 2.0 · 10 Ϫ16 A.
RESULTS AND DISCUSSION
The loss of [ 3 H]E2 binding detected in living MCF-7 cells may be relevant to a competitive mechanism involving hERa or hERb as reported in our previous publication. 10) Binding assays were performed with highly purified hERs to determine wether this occured. In contrast to E2 and 4-OH-Tam, 1 failed to compete with [ 3 H]E2 for binding to both ER isoforms (Figs. 2 and 3) . Discrepancies between binding data established on ERs in living cells (whole-cell assay) and purified hERs (hERa and hERb) have been recently reported by Kim and Katzenellenbogen. 36) According to those authors, if this difference in binding was due to a nonspecific association, we should have observed a higher binding affinity for the pure receptors hERa and/or hERb. Since we observed the opposite tendency (higher binding affinity for ERs in MCF-7 cells, Kdϭ2.5Ϯ0.91 nM), we can reject the possibility of such a nonspecific binding phenomenon. Thus the discrepancies appear to favor a mechanism in which coactivators could assume a suitable configuration of ERs to optimize the affinity of compound 1 for the receptors.
37) Down-regulation of ERs in the whole-cell assay, i.e., ligand induced degradation leading to its progressive elimination, [38] [39] [40] [41] The assessment of luciferase induction in MVLN cells confirms this view of an intracellular association of 1 with ER. We found 53% enhancement for compound 1 at 10 Ϫ6 M (control, 100%; E2, 178% at 10 Ϫ10 M; RU 58668, 34% at 10 Ϫ7 M), suggesting an estrogenic effect (Fig. 5) . 42) We next compared the transcriptional activity of 1 with coumestrol at concentrations ranging from 10 Ϫ10 to 10 Ϫ6 M. As reference standards, E2 10 Ϫ10 M and the pure antiestrogen RU 58668 10 Ϫ7 M were used. Whereas coumestrol provoked an expected increase in luciferase (estrogenicity) with a maximum of activity at 10 Ϫ6 M (287%), compound 1 produced a weaker increase (only 188%) at the same concentration suggesting a lower efficiency. In agreement with this result, coumestrol 10 Ϫ7 M exhibited such significant luciferase induction (Fig. 6) whereas compound 1 (Fig. 5a ) failed to exhibit a significant increase in luciferase induction (for comparison, note the activity of E2 and RU 58668, Fig. 7) . A comparison of the luciferase induction profiles of E2, coumestrol, and 1 revealed a marchedly lower potency of the latter two compounds (optimal luciferase increase was always reached at 10 Ϫ10 M E2). The decrease in the level of luciferase always seen with RU 58668 may be relevant to an inhibition of transcription induced by growth factors from either the serum or released by the cells (autocrine regulation).
In another experiment, we tested the ability of RU 58668 to inhibit the luciferase induced by coumestrol and compound 1. Figure 5b clearly shows inhibition of the luciferase activity induced by compound 1 when RU 58668 was added to the medium at 10 Ϫ7 M, which produced optimal inhibition. These results confirm that the estrogenic activity induced by compound 1 is mediated by ERs.
Since the transcriptional pointed to an estrogenic mechanism mediated by ERs, we determined the in situ localization of compound 1 in MCF-7 cells using ionic microscopy, a very sensitive imaging method to explore the localization of the intracellular targets of drugs. To carry out this experiment, we synthesized a fluor-labeled derivative of 1, i.e., compound 15. The advantage of such a labeled derivative is that fluor is not usually present in cells and therefore its detection in MCF-7 cells reflects the intracellular distribution of compound 15. In a preliminary phase of this experiment, we verified that compound 15 has estrogenic activity in MVLN cells similar to that of compound 1. A slightly weaker transcriptional activity with a maximal efficiency at 10 Ϫ6 M was seen, as shown in Fig. 8a . RU 58668 again inhibited the activity of compound 15, confirming the involvement of ER (Fig. 8b) .
Analytical microscopy of MCF-7 cells after 1.5 h of stimulation by fluorinated derivative 15 revealed an image at the mass of 19 corresponding to fluor 19 F. Figure 9 shows the intranuclear distribution of compound 15 at the mass of 19. The marked intranuclear distribution of fluor supports the concept of a direct binding of compound 15 to nuclear ERs.
Finally, the potential binding mode of compound 1 on ERs was investigated. This study was inspired by a recent article from Pike et al. 43) dealing with the ligand binding mode of nonsteroidal ligands within the hERa-LBD and hERb-LBD. Two types of contacts bonding to specific amino acids of the LBD are required for E2: the first concerns the 3-phenolic group (A-ring) and the second the 17b-hydroxyl group (Dring). In the hERa-LBD, the phenolic group binds to the residue Glu-353 (helix H3) of the hERa-LBD while the 17b-hydroxyl binds to the d nitrogen of the His-524 (helix H11) and the d oxygen of Glu-419 (loop 6-7) (Fig. 10a) . The donor and acceptor characteristics of the phenol at position 3 and of the hydroxyl at position 17b, respectively, are involved in these interactions. Even if the donor and acceptor characters of the 17b-hydroxyl are required for contacts with His-524 and Glu-419, the interaction with His-524 (donor character) is the most significant in terms of energy. 44) Moreover, it is now well established that this 17b-hydroxyl interaction with the His-524 region of the hERa-LBD is more important than that of the 3-phenolic group with the Glu-353 region, as reported by Wurtz et al. 45) For this reason, some methoxylated ligands exhibit good binding affinity for ERs. This is the case for TACE (or chlortrianisen), centchroman, 46) and apparently compound 1 10) (i.e., interaction of the oxygen of its methoxyl group with the His-524, donor interaction). Hence, the outcome of these considerations is that the methoxyl group of compound 1 would not interact with Glu-353, and should interact exlusively with the His-524 (but not with Glu-419) of hERa-LBD. Nevertheless, it is important to take into account the enzymatic metabolism conducting in vivo to the hydroxylated drugs. In this regard, we found that the 3-hydroxylated derivative of 1, i.e., 6,12-dihydro-3-methoxy-1-benzopyrano [3,4-b] [1, 4] benzothiazin-6-one did not enhance the activity or the binding affinity for ERs. 10) When the estrogenic effects of compounds 1 and 16 were compared, the results were unequivocal since they revealed no transcriptional activity of compound 16 (113% at 10 Ϫ6 M), whereas compound 1 exhibited a significant estrogenic effect (188% at 10 Ϫ6 M). These observations confirm that the methoxy group at position 3 of compound 1 favors an estrogenic effect, whereas its presence at position 9 is unfavorable. It is therefore highly probable that the 3-methoxy group of 1 lies in the hERa-LBD of residue His-524 (Fig. 10b) .
In conclusion, our results confirm a promising estrogenic effect of 1 similar to that of coumestrol. This activity appears to be mediated by intracellular ERs, of which the appropriate binding conformation could be stabilized by co-activators. We also determined the most probable binding mode of 1 within the hERa-LBD. Our results concerning this new family of coumarins with estrogenic activity suggest a potential use in the prevention of estrogen-dependent diseases in postmenopausal women. In this regard, it should be stressed that all these derivatives have been obtained by efficient synthesis, opening the possibility of a wide pharmacomodulation. Further experiments are required to confirm the involvement of co-activators in the estrogenic activity of compound 1.
